Biomarin Pharmaceutical Inc (BMRN) — Cash Flow-to-Debt Ratio
Biomarin Pharmaceutical Inc (BMRN) has a Cash Flow-to-Debt Ratio of 0.07x as of December 2025, meaning its operating cash flow of $99.64 Million could theoretically repay 0% of its total liabilities ($1.51 Billion) in one year. See free cash flow generation of Biomarin Pharmaceutical Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Biomarin Pharmaceutical Inc Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Biomarin Pharmaceutical Inc across 28 annual periods. Also explore net asset growth rate of Biomarin Pharmaceutical Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Biomarin Pharmaceutical Inc (1998–2025)
Year-by-year debt coverage analysis for Biomarin Pharmaceutical Inc. For market capitalisation and broader financial context, see Biomarin Pharmaceutical Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.55x | $827.99 Million | $1.51 Billion | ▲ +27.7% |
| 2024 | 0.43x | $572.84 Million | $1.33 Billion | ▲ +410.8% |
| 2023 | 0.08x | $159.26 Million | $1.89 Billion | ▼ -15.1% |
| 2022 | 0.10x | $175.90 Million | $1.77 Billion | ▼ -43.5% |
| 2021 | 0.18x | $304.54 Million | $1.73 Billion | ▲ +258.7% |
| 2020 | 0.05x | $85.36 Million | $1.74 Billion | ▲ +59.2% |
| 2019 | 0.03x | $48.26 Million | $1.57 Billion | ▲ +122.3% |
| 2018 | 0.01x | $20.21 Million | $1.46 Billion | ▲ +388.5% |
| 2017 | 0.00x | $-8.76 Million | $1.82 Billion | ▲ +97.4% |
| 2016 | -0.18x | $-227.84 Million | $1.26 Billion | ▼ -8.6% |
| 2015 | -0.17x | $-221.69 Million | $1.33 Billion | ▼ -118.4% |
| 2014 | -0.08x | $-73.54 Million | $962.56 Million | ▼ -15.7% |
| 2013 | -0.07x | $-59.63 Million | $903.02 Million | ▼ -307.2% |
| 2012 | 0.03x | $17.61 Million | $552.58 Million | ▼ -9.5% |
| 2011 | 0.04x | $18.75 Million | $532.66 Million | ▲ +2.4% |
| 2010 | 0.03x | $18.75 Million | $545.37 Million | ▼ -76.7% |
| 2009 | 0.15x | $87.73 Million | $594.98 Million | ▲ +1112.5% |
| 2008 | -0.01x | $-9.18 Million | $630.02 Million | ▲ +73.5% |
| 2007 | -0.05x | $-34.49 Million | $627.55 Million | ▲ +62.1% |
| 2006 | -0.14x | $-50.09 Million | $345.63 Million | ▲ +36.9% |
| 2005 | -0.23x | $-62.68 Million | $272.76 Million | ▼ -6.2% |
| 2004 | -0.22x | $-65.14 Million | $300.94 Million | ▲ +59.9% |
| 2003 | -0.54x | $-74.80 Million | $138.49 Million | ▲ +87.8% |
| 2002 | -4.44x | $-53.59 Million | $12.07 Million | ▼ -136.0% |
| 2001 | -1.88x | $-23.07 Million | $12.26 Million | ▼ -1.2% |
| 2000 | -1.86x | $-12.90 Million | $6.94 Million | ▲ +25.7% |
| 1999 | -2.50x | $-12.94 Million | $5.17 Million | ▲ +34.8% |
| 1998 | -3.84x | $-8.10 Million | $2.11 Million | — |